Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor
Abstract Background Cachexia is a multiorganic syndrome associated with cancer, characterized by bod...
Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) liga...
Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In ...
Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic o...
SummaryMuscle wasting and cachexia have long been postulated to be key determinants of cancer-relate...
Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligan...
Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligan...
Abstract Background Cancer cachexia increases morbidity and mortality, and blocking of activin recep...
Cancer cachexia is a condition of severe frailty and fatigue, associated with the loss of skeletal m...
SummaryMuscle wasting and cachexia have long been postulated to be key determinants of cancer-relate...
Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor liga...
Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and i...
Fulltext embargoed for: 12 months post date of publicationIn models of cancer cachexia, inhibiting t...
BACKGROUND: Cancer-associated cachexia and muscle wasting are considered key determinants of cancer-...
The skeletal muscle wasting, occurring during cancer cachexia (CC), is a factor of poor prognosis. I...
Abstract Background Cachexia is a multiorganic syndrome associated with cancer, characterized by bod...
Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) liga...
Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In ...
Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic o...
SummaryMuscle wasting and cachexia have long been postulated to be key determinants of cancer-relate...
Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligan...
Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligan...
Abstract Background Cancer cachexia increases morbidity and mortality, and blocking of activin recep...
Cancer cachexia is a condition of severe frailty and fatigue, associated with the loss of skeletal m...
SummaryMuscle wasting and cachexia have long been postulated to be key determinants of cancer-relate...
Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor liga...
Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and i...
Fulltext embargoed for: 12 months post date of publicationIn models of cancer cachexia, inhibiting t...
BACKGROUND: Cancer-associated cachexia and muscle wasting are considered key determinants of cancer-...
The skeletal muscle wasting, occurring during cancer cachexia (CC), is a factor of poor prognosis. I...
Abstract Background Cachexia is a multiorganic syndrome associated with cancer, characterized by bod...
Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) liga...
Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In ...
DOI
Add to ORKG